David MD - Mineralys Therapeutics Chief Officer
| MLYS Stock | 13.06 0.13 1.01% |
Executive
David MD is Chief Officer of Mineralys Therapeutics Common
| Age | 69 |
| Phone | 888 378 6240 |
| Web | https://mineralystx.com |
Mineralys Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2009) % which means that it has lost $0.2009 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2911) %, meaning that it created substantial loss on money invested by shareholders. Mineralys Therapeutics' management efficiency ratios could be used to measure how well Mineralys Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Melanie Hart | Pool Corporation | 51 | |
| Donna Williams | Pool Corporation | N/A | |
| Lindsey Rynard | Employers Holdings | N/A | |
| Ty Vukelich | Employers Holdings | N/A | |
| Allan Churchmack | Arhaus Inc | N/A | |
| Kristopher Neff | Pool Corporation | N/A | |
| George Carbonar | Employers Holdings | 62 | |
| Wendy Watson | Arhaus Inc | N/A | |
| Carolyne Large | Pool Corporation | N/A | |
| James Bogdan | LB Foster | N/A | |
| Stephanie Listwak | LB Foster | N/A | |
| Kelley Kage | Employers Holdings | N/A | |
| Bonnie Bishop | Brp Group | N/A | |
| Corbyn Lichon | Brp Group | 31 | |
| Walker Saik | Pool Corporation | N/A | |
| Christina Ozuna | Employers Holdings | N/A | |
| Matthew Hendricksen | Employers Holdings | 44 | |
| Ann Smith | Employers Holdings | N/A | |
| Jake Fuellhart | LB Foster | N/A | |
| Kendall Large | Pool Corporation | N/A | |
| Peter Jones | LB Foster | 56 | |
Management Performance
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.2 |
Mineralys Therapeutics Leadership Team
Elected by the shareholders, the Mineralys Therapeutics' board of directors comprises two types of representatives: Mineralys Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mineralys. The board's role is to monitor Mineralys Therapeutics' management team and ensure that shareholders' interests are well served. Mineralys Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mineralys Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert McKean, Senior CMC | ||
| Adam Levy, CFO Secretary | ||
| Sarah Foster, Vice Resources | ||
| Danielle Bradbury, Senior Assurance | ||
| Jon Congleton, CEO Director | ||
| Cindy Berejikian, Executive Operations | ||
| Minji MBA, Chief Officer | ||
| Jessica Ibbitson, Senior Operations | ||
| Jeffrey Fellows, Senior Affairs | ||
| David MD, Chief Officer | ||
| MD MPH, Founder Chairman |
Mineralys Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mineralys Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | 332.68 M | ||||
| Shares Outstanding | 49.63 M | ||||
| Shares Owned By Insiders | 2.95 % | ||||
| Shares Owned By Institutions | 92.25 % | ||||
| Number Of Shares Shorted | 1.01 M | ||||
| Price To Book | 2.67 X | ||||
| EBITDA | (84.66 M) | ||||
| Net Income | (71.9 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mineralys Therapeutics Common. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Mineralys Stock analysis
When running Mineralys Therapeutics' price analysis, check to measure Mineralys Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics is operating at the current time. Most of Mineralys Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics' price. Additionally, you may evaluate how the addition of Mineralys Therapeutics to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is Mineralys Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mineralys Therapeutics. If investors know Mineralys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mineralys Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mineralys Therapeutics is measured differently than its book value, which is the value of Mineralys that is recorded on the company's balance sheet. Investors also form their own opinion of Mineralys Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mineralys Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mineralys Therapeutics' market value can be influenced by many factors that don't directly affect Mineralys Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mineralys Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mineralys Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mineralys Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.